Skip to main content
Publications
Mazurek M, Teutsch C, Diener H-C, Dubner SJ, Halperin JL, Ma C-S, Rothman KJ, Paquette M, Zint K, Franca L, Lu S, Bartels DB, Huisman MV, Lip GYH, GLORIA-AF Investigators. Safety and effectiveness of dabigatran at 2 years: final outcomes from Phase II of the GLORIA-AF registry program. Am Heart J. 2019 Dec;218:123-7. doi: 10.1016/j.ahj.2019.08.012
Cainzos-Achirica M, Rebordosa C, Vela E, Cleries M, Matsushita K, Plana E, Rivero-Ferrer E, Enjuanes C, Jimenez-Marrero S, Garcia-Rodriguez LA, Comin-Colet J, Perez-Gutthann S. Challenges of evaluating chronic heart failure and acute heart failure events in research studies using large health care databases. Am Heart J. 2018 Aug;202:76-83. doi: 10.1016/j.ahj.2018.05.005
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895
Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015 Jul;170(1):85-95. doi: 10.1111/bjh.13399
Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K, Ackermann D, Clemens A, Bartels DB. Design and rationale of global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014 Mar;167(3):329-34. doi: 10.1016/j.ahj.2013.12.006
Harrison CN, Mesa RA, Kiladjian J-J, Al-Ali H-K, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol. 2013 Jul;162(2):229-39. doi: 10.1111/bjh.12375
Abu-Assi E, Ferreira-Gonzalez I, Ribera A, Marsal JR, Cascant P, Heras M, Bueno H, Sanchez PL, Aros F, Marrugat J, Garcia-Dorado D, Pena-Gil C, Gonzalez-Juanatey JR, Permanyer-Miralda G. Do GRACE (Global Registry of Acute Coronary events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes? Am Heart J. 2010 Nov;160(5):826-34. doi: 10.1016/j.ahj.2010.06.053
Ferreira-Gonzalez I, Permanyer-Miralda G, Heras M, Cunat J, Civeira E, Aros F, Rodriguez JJ, Sanchez PL, Marsal JR, Ribera A, Marrugat J, Bueno H, MASCARA study group. Patterns of use and effectiveness of early invasive strategy in non-ST-segment elevation acute coronary syndromes: an assessment by propensity score. Am Heart J. 2008 Nov;156(5):946-53. doi: 10.1016/j.ahj.2008.06.032
Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FMJr, Tsiatis AA, Wilan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J. 2005 Mar;149(3):434-43.